Results: -Both technologies achieved high levels of satisfaction (-1%, 95% CI (-11, 9)). Menstrual scores were also similar (4%, 95% CI (-7, 19)) Microwave had a significantly shorter operating time, reduced usage of antiemetics and opiate analgesia, increased discharge by six hours and fewer device failures.
Introduction
The surgical treatment of heavy menstrual loss has been revolutionised over the last fifteen years with the widespread introduction of endometrial ablation.
First generation hysteroscopic endometrial ablative techniques (transcervical resection of the endometrium (TCRE), rollerball and laser) are successful but require high levels of skill. [1] [2] [3] [4] [5] This led to the development of second generation techniques which are technically much simpler to perform, but the majority of which are not performed under direct hysteroscopic vision. [1] [2] [3] [4] [5] There is a wealth of robust evidence comparing first generation endometrial ablation techniques to hysterectomy [1] [2] [3] [4] [5] whilst second generation techniques have been compared with first generation techniques, in order to prove their efficacy. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Good quality randomised trials comparing clinical outcomes and costs between the different varieties of second generation ablative techniques are less common. [16] [17] [18] We aimed to rectify this with a comparison of the two second generation techniques most commonly used in the UK, microwave endometrial ablation (MEA TM ) and thermal balloon endometrial ablation (TBall). This is in accordance with a recommendation from the National institute for Health and Clinical Excellence (NICE). 
Interventions
Procedures were undertaken in the post menstrual phase. This was either achieved by natural cycle or by a withdrawal bleed induced by Provera 10mg twice a day or norethisterone 5mg three times a day for seven days.
Treatment was scheduled ten days after stopping the tablets. The TBall procedure was adapted from the standard method 9 by adding fluid to the balloon if necessary during the treatment cycle in order to maintain intracavity pressure at 160 -180mmHg. Total procedure time was taken from insertion of intra venous access to the patient leaving theatre. Procedure time (ablation) was taken from insertion of probe to removal of probe.
Post operatively, once comfortable, voiding and tolerating diet; patients were discharged with an information sheet and contact telephone number.
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Objectives
To compare the clinical outcomes of microwave endometrial ablation (MEA   TM   ) and thermal balloon ablation (TBall) for the treatment of heavy menstrual bleeding.
Outcomes
Primary outcomes were satisfaction and menstrual scores one year.
Secondary outcomes were operative differences, acceptability of treatment, and changes in health related quality of life..
Patients completed pre-operative questionnaires to obtain baseline menstrual details. These included both PBLAC 22 and a menstrual bleeding and pain score used in previous endometrial ablation trials from this centre. 7, [23] [24] [25] The woman rated the blood loss on a scale from 1 least to 5 greatest for each day of her period. These values were then added for a total menstrual blood loss score. Menstrual pain was rated in an identical manner, in order to give a total pain score for the period. Baseline health-related quality of life parameters (Short form 12 26 and EQ-5D 27) and an assessment of anxiety/ depression (Hospital Anxiety and Depression Score 28 ) were also completed.
The questionnaires were repeated post treatment, at two weeks, six months and one year following the procedure.
Acceptability of the procedure and a pain questionnaire were completed on the day of surgery and two weeks post operatively. Acceptability of the procedure was assessed using a six-point scale and on a 10cm visual -10 -analogue scale (0cm = totally acceptable, 10cm = totally unacceptable). Pain was assessed using a modified version of the McGill Questionnaire
29
.
Satisfaction with the outcome was measured at one year post procedure on a six-point scale from totally satisfied through to totally dissatisfied.
Sample Size
It was calculated a priori that 290 patients would be required to achieve 80%
power to detect a 12% difference in those totally or generally satisfied with treatment. This number gives 80% power to detect a 15% difference in amenorrhoea rates (2p < 0.05). This is based on the only randomised trial evidence that established amenorrhoea rates for MEA™ at one year of 40 % and of TBall of around 20%. 20, 21 This number of patients would also give 90%
power to detect a difference in menstrual scores (pictorial blood loss assessment chart, PBLAC) of 10, again significant at the 5% level. To account for drop outs 320 women were recruited to the trial. Previous ablation studies at this centre have shown up to a 20% loss to follow up by five years.
Randomisation
Patients were randomised in a ratio of 1:1 to the MEA TM and TBall arms of the study. Computer generated randomly permuted blocks were used with a telephone randomisation service based on a separate site to achieve concealment.
Blinding -11 -
The treatment allocation was not revealed to the participants during the course of the study. Outcome assessment was collected by means of patient completed questionnaires with the exception of the operative questionnaire data. The data was entered and analysed independently by researchers unaware of the treatment allocation.
Statistical analysis
All statistical analyses were carried out using SPSS v14 unless otherwise stated. Intention to treat analysis was utilised; that is each participant remained in their initially allocated group irrespective of the treatment received. A 95% confidence interval for the difference in proportions was calculated in Excel using Newcombe's method. 30 Health related quality of life measures (EQ-5D and SF-12 scores) were compared using a linear regression model to estimate the mean difference between groups, after adjusting for baseline values. Where appropriate, to account for skewness and an excess number of zeroes in an outcome, a zero inflated negative binomial regression model 31 was used to estimate the incidence rate ratio (IRR) and 95% confidence intervals between groups, using STATA 9SE.
Adjustment was made in the model for baseline values. The McGill pain score was generated using the rank weight method with a comparison between groups made using a Mann-Whitney test. The acceptability visual analogue scale was also compared using a Mann-Whitney test. Procedure times were compared using an independent t-test. A zero value was imputed for twelve months bleeding/pain scores PBLAC where the participant had -12 - AS, a specialist registrar (trainee) undertook the majority of the procedures under indirect supervision, (93%) with a consultant, K.C., undertaking the remainder.
Baseline characteristics for both groups were very similar ( Table 1 ). Operative differences show a significant difference between MEA TM and TBall in total procedure time (from insertion of intravenous access to leaving theatre, (mean difference -5.9 min, 95% CI -8.5 min, -3.3 min) and in procedure time (insertion of probe to removal of probe (mean difference -6.6 min; 95% CI -7.4 min, -5.8 min) ( Table 2 ). The median procedure related discomfort of both procedures was 3 on a scale of 1 none to 6 excruciating).
A further difference was demonstrated in the requirement for opiate analgesia and antiemetic medication between the two groups (Table 3) , with the MEA TM group requiring significantly less (difference -22%, 95% CI (-32%, -11%)).
-14 - High levels of acceptability with the procedure were found in both groups at two weeks with 118 (81%) of the MEA™ group and 122 (87%) of the TBall group describing their treatment as totally or generally acceptable (difference in proportion -6%; 95% CI -15%, 2%). There was a high level of satisfaction at twelve months with 109 (76%) of the MEA™ group and 103 (77%) of the TBall group described themselves as totally or generally satisfied with their procedure (difference in proportion -1%, 95% CI -11%, 9 %). The majority of women 91% for MEA TM and 92% for TBall would recommend the treatment to a friend at twelve months.
Menstrual outcomes between the two groups were comparable at twelve months (Table 4 ) both for PBLAC, pain and bleeding scores. 41% of the MEA TM group and 38% of the TBall group were amenorrhoeic. There were six hysterectomies in the MEA TM group and six in the TBall group (0.03%, 95% CI (-5%, 5%) ). Quality of life scores (both physical and mental components)
were not significantly different between the groups (Figure 2 ).
Discussion
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This study demonstrates that MEA TM and TBall are both acceptable treatments which achieve high satisfaction rates for patients wishing treatment for their heavy menses. Patient quality of life shows an overall sustained improvement following both treatments.
Thermal balloon ablation achieved a high rate of amenorrhoea in this study when compared to previous reported randomised controlled trials. 9, 17, 18 This may be due to the active circulation of fluid within the Thermachoice III catheters. 33 We feel that the addition of fluid into the balloon during the treatment cycle to maintain the treatment pressure above 160mmhg may also be important. This is not recommended practice by the manufacturer, at The operative time differences between the two groups were predictable.
TBall requires several minutes in order to achieve a stable intrauterine pressure and pre heating phase prior to the eight minute treatment cycle. The treatment cycle for MEA TM can begin immediately after insertion of the probe.
Procedure failures are an important consideration when choosing a second generation method. There was only one MEA™ device failure with eleven device failures in the TBall arm. These tended to be in women with large cavities and wide intercornual distances where it was not possible to achieve adequate intrauterine pressures in order to start the treatment cycle. The device failure in the MEA™ arm was due to moisture within the data cable. If disposable MEA™ probes (Femwave™) had been used this would not have occurred.
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